
Schleich says biologic switching in severe asthma should follow exacerbation phenotyping and discusses response predictors and standardized follow-up.

Florence Schleich, MD, PhD, a respiratory physician at the University of Liège in Belgium.

Schleich says biologic switching in severe asthma should follow exacerbation phenotyping and discusses response predictors and standardized follow-up.

Florence Schleich, MD, PhD, explains how exacerbation phenotypes and useful biomarkers shift across anti-IL-5, anti-IL-5R, and anti-TSLP therapies.